| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
250,132 |
394,694 |
1,191,358 |
1,409,424 |
| Total Sell Value |
$16,523,610 |
$24,268,720 |
$69,977,407 |
$78,350,476 |
| Total People Sold |
8 |
9 |
11 |
11 |
| Total Sell Transactions |
21 |
39 |
80 |
83 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Przybyl Arthur |
President and CEO |
• • – |
2019-04-16 |
4 |
D |
$68.60 |
$116,071 |
D/D |
(1,692) |
232,589 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2019-04-07 |
4 |
D |
$70.50 |
$27,636 |
D/D |
(392) |
58,696 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2019-04-07 |
4 |
D |
$70.50 |
$149,108 |
D/D |
(2,115) |
234,281 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2019-04-07 |
4 |
D |
$70.50 |
$10,152 |
D/D |
(144) |
75,169 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2019-04-06 |
4 |
D |
$70.50 |
$46,460 |
D/D |
(659) |
59,088 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2019-04-06 |
4 |
D |
$70.50 |
$231,381 |
D/D |
(3,282) |
236,396 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2019-04-06 |
4 |
D |
$70.50 |
$23,759 |
D/D |
(337) |
75,313 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2019-04-06 |
4 |
D |
$70.50 |
$43,146 |
D/D |
(612) |
25,450 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2019-03-31 |
4 |
D |
$70.54 |
$38,515 |
D/D |
(546) |
59,747 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2019-03-31 |
4 |
D |
$70.54 |
$188,906 |
D/D |
(2,678) |
239,678 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2019-03-31 |
4 |
D |
$70.54 |
$35,764 |
D/D |
(507) |
26,062 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2019-03-31 |
4 |
D |
$70.54 |
$19,610 |
D/D |
(278) |
75,650 |
|
- |
|
| Walsh Patrick D |
Director |
– • – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,991 |
3,791 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
12,451 |
60,293 |
|
- |
|
| Penn Thomas A. |
Director |
– • – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,991 |
14,301 |
|
- |
|
| Marken James G. |
SVP Ops & Prod Dev |
• – – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,848 |
75,928 |
|
- |
|
| Nash David |
Director |
– • – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,991 |
3,791 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
37,280 |
242,356 |
|
- |
|
| Brown Robert E. Jr |
Director |
– • – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,584 |
20,352 |
|
- |
|
| Haughey Thomas |
Director |
– • – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,991 |
3,791 |
|
- |
|
| Carey Stephen P. |
Vice President and CFO |
• – – |
2019-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
12,451 |
26,569 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2019-03-19 |
4 |
S |
$63.51 |
$179,289 |
D/D |
(2,823) |
205,076 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2019-03-18 |
4 |
S |
$63.53 |
$1,575,671 |
D/D |
(24,802) |
205,076 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2019-03-13 |
4 |
S |
$64.43 |
$299,646 |
D/D |
(4,651) |
47,842 |
|
- |
|
| Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
• – – |
2019-03-13 |
4 |
OE |
$33.00 |
$153,483 |
D/D |
4,651 |
52,493 |
|
- |
|
707 Records found
|
|
Page 11 of 29 |
|
|
0.14 (0.21%) 
